<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "7: Royalty ", fill: "#98ff98"},
{source: "7: Royalty ", target: "7: manufacturing", fill: "#98ff98"},
{source: "7: Royalty ", target: "9: future growth", fill: "#663854"},
{source: "9: future growth", target: "9: significant", fill: "#663854"},
{source: "9: significant", target: "9: future revenues depend on", fill: "#663854"},
{source: "9: future revenues depend on", target: "9: continued commercial success", fill: "#663854"},
{source: "9: future growth", target: "10: will continue", fill: "#efdecd"},
{source: "10: will continue", target: "10: United States ", fill: "#efdecd"},
{source: "10: United States ", target: "10: foreign market", fill: "#efdecd"},
{source: "10: will continue", target: "11: factors may", fill: "#e25822"},
{source: "11: factors may", target: "11: perception by physicians", fill: "#e25822"},
{source: "11: perception by physicians", target: "11: community", fill: "#e25822"},
{source: "11: community", target: "11: effectiveness", fill: "#e25822"},
{source: "11: effectiveness", target: "11: United States ", fill: "#e25822"},
{source: "11: United States ", target: "11: efforts outside", fill: "#e25822"},
{source: "11: efforts outside", target: "11: additional", fill: "#e25822"},
{source: "11: additional", target: "11: Merck KGaAs ", fill: "#e25822"},
{source: "11: Merck KGaAs ", target: "11: indications", fill: "#e25822"},
{source: "11: indications", target: "11: unfavorable publicity concerning", fill: "#e25822"},
{source: "11: unfavorable publicity concerning", target: "11: competitive", fill: "#e25822"},
{source: "11: competitive", target: "11: treatments", fill: "#e25822"},
{source: "11: treatments", target: "11: availability", fill: "#e25822"},
{source: "11: availability", target: "11: thirdparty reimbursement", fill: "#e25822"},
{source: "11: thirdparty reimbursement", target: "11: adequate supplies", fill: "#e25822"},
{source: "11: adequate supplies", target: "11: Regulatory ", fill: "#e25822"},
{source: "11: Regulatory ", target: "11: developments", fill: "#e25822"},
{source: "11: developments", target: "11: manufacture", fill: "#e25822"},
{source: "11: manufacture", target: "11: continued use", fill: "#e25822"},
{source: "11: continued use", target: "11: revenues would decline", fill: "#e25822"},
{source: "11: revenues would decline", target: "11: which would impact", fill: "#e25822"},
{source: "11: which would impact", target: "11: profitability", fill: "#e25822"},
{source: "11: profitability", target: "11: common stock", fill: "#e25822"},
{source: "11: factors may", target: "23: significant competition", fill: "#ff0028"},
{source: "23: significant competition", target: "23: Avastin ", fill: "#ff0028"},
{source: "23: Avastin ", target: "23: bevacizumab", fill: "#ff0028"},
{source: "23: bevacizumab", target: "23: Genentech Inc", fill: "#ff0028"},
{source: "23: significant competition", target: "24: approved by", fill: "#c19a6b"},
{source: "24: approved by", target: "24: firstline treatment", fill: "#c19a6b"},
{source: "24: firstline treatment", target: "24: patients with metastatic colorectal cancer", fill: "#c19a6b"},
{source: "24: patients with metastatic colorectal cancer", target: "24: chemotherapeutic", fill: "#c19a6b"},
{source: "24: chemotherapeutic", target: "24: biopharmaceutical", fill: "#c19a6b"},
{source: "24: biopharmaceutical", target: "24: manufactured", fill: "#c19a6b"},
{source: "24: manufactured", target: "24: Roche Laboratories Inc", fill: "#c19a6b"},
{source: "24: approved by", target: "27: development", fill: "#c33"},
{source: "27: development", target: "27: biotechnology", fill: "#c33"},
{source: "27: biotechnology", target: "27: pharmaceutical companies", fill: "#c33"},
{source: "27: pharmaceutical companies", target: "27: clinical trials", fill: "#c33"},
{source: "27: clinical trials", target: "27: marketing may", fill: "#c33"},
{source: "27: marketing may", target: "27: priced competitively", fill: "#c33"},
{source: "27: priced competitively", target: "27: compete with", fill: "#c33"},
{source: "27: compete with", target: "27: indication", fill: "#c33"},
{source: "27: indication", target: "27: indications", fill: "#c33"},
{source: "27: development", target: "32: regulatory", fill: "#ffc1cc"},
{source: "32: regulatory", target: "32: candidates", fill: "#ffc1cc"},
{source: "32: candidates", target: "32: product candidates", fill: "#ffc1cc"},
{source: "32: regulatory", target: "40: revenues will diminish", fill: "#c19a6b"},
{source: "40: revenues will diminish", target: "40: collaborators fail", fill: "#c19a6b"},
{source: "40: collaborators fail", target: "40: adequate reimbursement", fill: "#c19a6b"},
{source: "40: adequate reimbursement", target: "40: from thirdparty payors", fill: "#c19a6b"},
{source: "40: revenues will diminish", target: "41: based on sales", fill: "#318ce7"},
{source: "41: based on sales", target: "41: product by", fill: "#318ce7"},
{source: "41: product by", target: "41: collaborators", fill: "#318ce7"},
{source: "41: collaborators", target: "41: BMS and Merck KGaA The ", fill: "#318ce7"},
{source: "41: BMS and Merck KGaA The ", target: "41: continuing efforts", fill: "#318ce7"},
{source: "41: continuing efforts", target: "41: government", fill: "#318ce7"},
{source: "41: government", target: "41: thirdparty", fill: "#318ce7"},
{source: "41: thirdparty", target: "41: thirdparty payors", fill: "#318ce7"},
{source: "41: thirdparty payors", target: "41: provide adequate coverage", fill: "#318ce7"},
{source: "41: provide adequate coverage", target: "41: reimbursement", fill: "#318ce7"},
{source: "41: reimbursement", target: "41: product physicians may", fill: "#318ce7"},
{source: "41: based on sales", target: "START_HERE", fill: "#318ce7"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Pharmaceuticals Biotechnology and Life Sciences</td>
    </tr>
    <tr>
      <td>Biotechnology</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Pharmaceuticals</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Leadership</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Material Aid</td>
    </tr>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Rally support</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Offer peace proposal</td>
    </tr>
    <tr>
      <td>Consult</td>
    </tr>
    <tr>
      <td>Reward</td>
    </tr>
    <tr>
      <td>Travel to meet</td>
    </tr>
    <tr>
      <td>Complain</td>
    </tr>
    <tr>
      <td>Sanction</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacturing">Manufacturing</a></td>
      <td>Manufacturing is the creation or production of goods with the help of equipment, labor, machines, tools, and chemical or biological processing or formulation. It is the essence of secondary sector of the economy.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacturing_Consent">Manufacturing Consent</a></td>
      <td>Manufacturing Consent: The Political Economy of the Mass Media is a 1988 book by Edward S. Herman and Noam Chomsky. It argues that the mass communication media of the U.S. "are effective and powerful ideological institutions that carry out a system-supportive propaganda function, by reliance on market forces, internalized assumptions, and self-censorship, and without overt coercion", by means of the propaganda model of communication.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacturing_engineering">Manufacturing engineering</a></td>
      <td>Manufacturing engineering is a branch of professional engineering that shares many common concepts and ideas with other fields of engineering such as mechanical, chemical, electrical, and industrial engineering. \nManufacturing engineering requires the ability to plan the practices of manufacturing; to research and to develop tools, processes, machines and equipment; and to integrate the facilities and systems for producing quality products with the optimum expenditure of capital.The manufacturing or production engineer's primary focus is to turn raw material into an updated or new product in the most effective, efficient &amp; economic way possible.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacturing_cost">Manufacturing cost</a></td>
      <td>Manufacturing cost is the sum of costs of all resources consumed in the process of making a product. The manufacturing cost is classified into three categories: direct materials cost, direct labor cost and manufacturing overhead.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Murata_Manufacturing">Murata Manufacturing</a></td>
      <td>Murata Manufacturing Co., Ltd. (株式会社村田製作所, Kabushiki-gaisha Murata Seisakusho) is a Japanese manufacturer of electronic components, based in Nagaokakyo, Kyoto.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Significant_figures">Significant figures</a></td>
      <td>Significant figures (also known as the significant digits, precision or resolution) of a number in positional notation are digits in the number that are reliable and necessary to indicate the quantity of something.\nIf a number expressing the result of a measurement (e.g., length, pressure, volume, or mass) has more digits than the number of digits allowed by the measurement resolution, then only as many digits as allowed by the measurement resolution are reliable, and so only these can be significant figures.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bit_numbering">Bit numbering</a></td>
      <td>In computing, bit numbering is the convention used to identify the bit positions in a binary number.\n\n\n== Bit significance and indexing ==\n\nIn computing, the least significant bit (LSB) is the bit position in a binary integer representing the binary 1s place of the integer.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Significant_Others">Significant Others</a></td>
      <td>The term significant other (SO) has different uses in psychology and in colloquial language. Colloquially "significant other" is used as a gender-neutral term for a person's partner in an intimate relationship without disclosing or presuming anything about marital status, relationship status, gender identity, or sexual orientation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/United_States">United States</a></td>
      <td>The United States of America (U.S.A. or USA), commonly known as the United States (U.S. or US) or America, is a country primarily located in North America. It consists of 50 states, a federal district, five major unincorporated territories, 326 Indian reservations, and nine minor outlying islands.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/President_of_the_United_States">President of the United States</a></td>
      <td>The president of the United States (POTUS) is the head of state and head of government of the United States of America. The president directs the executive branch of the federal government and is the commander-in-chief of the United States Armed Forces.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/United_States_Congress">United States Congress</a></td>
      <td>The United States Congress is the legislature of the federal government of the United States. It is bicameral, being composed of a lower body, the House of Representatives, and an upper body, the Senate.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/United_States_Navy">United States Navy</a></td>
      <td>The United States Navy (USN) is the maritime service branch of the United States Armed Forces and one of the eight uniformed services of the United States. It is the largest and most powerful navy in the world, with the estimated tonnage of its active battle fleet alone exceeding the next 13 navies combined, including 11 U.S. allies or partner nations as of 2015.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Republican_Party_(United_States)">Republican Party (United States)</a></td>
      <td>The Republican Party, also referred to as the GOP ("Grand Old Party"), is one of the two major contemporary political parties in the United States, along with its main historic rival, the Democratic Party.\nThe GOP was founded in 1854 by anti-slavery activists who opposed the Kansas–Nebraska Act, which allowed for the potential expansion of chattel slavery into the western territories.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_presidents_of_the_United_States">List of presidents of the United States</a></td>
      <td>The president of the United States is the head of state and head of government of the United States, indirectly elected to a four-year term by the American people through the Electoral College. The office holder leads the executive branch of the federal government and is the commander-in-chief of the United States Armed Forces.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Research_and_development">Research and development</a></td>
      <td>Research and development (R&amp;D or R+D), known in Europe as research and technological development (RTD), is the set of innovative activities undertaken by corporations or governments in developing new services or products, and improving existing ones. Research and development constitutes the first stage of development of a potential new service or the production process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Profitability_analysis">Profitability analysis</a></td>
      <td>In cost accounting, profitability analysis is an analysis of the profitability of an organisation's output. Output of an organisation can be grouped into products, customers, locations, channels and/or transactions.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Customer_profitability">Customer profitability</a></td>
      <td>Customer profitability (CP) is the profit the firm makes from serving a customer or customer group over a specified period of time, specifically the difference between the revenues earned from and the costs associated with the customer relationship in a specified period. According to Philip Kotler,"a profitable customer is a person, household or a company that overtime, yields a revenue stream that exceeds by an acceptable amount the company's cost stream of attracting, selling and servicing the customer."\nCalculating customer profit is an important step in understanding which customer relationships are better than others.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Food_and_Drug_Administration">Food and Drug Administration</a></td>
      <td>The United States Food and Drug Administration (FDA or USFDA) is a federal agency of the Department of Health and Human Services. The FDA is responsible for protecting and promoting public health through the control and supervision of food safety, tobacco products, dietary supplements, prescription and over-the-counter pharmaceutical drugs (medications), vaccines, biopharmaceuticals, blood transfusions, medical devices, electromagnetic radiation emitting devices (ERED), cosmetics, animal foods &amp; feed and veterinary products.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Approved_school">Approved school</a></td>
      <td>An approved school was a type of residential institution in the United Kingdom to which young people could be sent by a court, usually for committing offences but sometimes because they were deemed to be beyond parental control. They were modelled on ordinary boarding schools, from which it was relatively easy to leave without permission.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Approved_drug">Approved drug</a></td>
      <td>An approved drug is a medicinal preparation that has been validated for a therapeutic use by a ruling authority of a government. This process is usually specific by country, unless specified otherwise.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/British_Approved_Name">British Approved Name</a></td>
      <td>A British Approved Name (BAN) is the official, non-proprietary, or generic name given to a pharmaceutical substance, as defined in the British Pharmacopoeia (BP). The BAN is also the official name used in some countries around the world, because starting in 1953, proposed new names were evaluated by a panel of experts from WHO in conjunction with the BP commission  to ensure naming consistency worldwide (an effort leading to the International Nonproprietary Name system).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Approved_Premises">Approved Premises</a></td>
      <td>In the United Kingdom, Approved Premises (AP), formerly known as probation or bail hostels, are residential units which house ex-offenders in the community. They are recognised under the Offender Management Act 2007.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Development/For!">Development/For!</a></td>
      <td>Development/For! (Latvian: Attīstībai/Par!, AP!) is a liberal political alliance in Latvia.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Human_development">Human development</a></td>
      <td>The Human Development Index (HDI) is a statistic composite index of life expectancy, education (mean years of schooling completed and expected years of schooling upon entering the education system), and per capita income indicators, which are used to rank countries into four tiers of human development. A country scores a higher level of HDI when the lifespan is higher, the education level is higher, and the gross national income GNI (PPP) per capita is higher.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Development_hell">Development hell</a></td>
      <td>Development hell, development purgatory, and development limbo are media and software industry jargon for a project, concept, or idea that remains in development for an especially long time, often moving between different crews, scripts, game engines, or studios before it progresses to production, if it ever does. Projects in development hell are usually not released until development has reached a satisfying state worthy of being released, ready for production.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Aerie_Pharmaceuticals">Aerie Pharmaceuticals</a></td>
      <td>Aerie Pharmaceuticals Inc. (Nasdaq: AERI) is a publicly traded, clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/MediGene">MediGene</a></td>
      <td>Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. Medigene is working on the development of immunotherapies to enhance T cell activity against solid cancers.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Pursuit_of_Nazi_collaborators">Pursuit of Nazi collaborators</a></td>
      <td>The pursuit of Nazi collaborators refers to the post-World War II pursuit and apprehension of individuals who were not citizens of the Third Reich at the outbreak of World War II but collaborated with the Nazi regime during the war. Hence, this article does not cover former members of the NSDAP and their fates after the war.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Unofficial_collaborator">Unofficial collaborator</a></td>
      <td>An unofficial collaborator or IM (German: [iˈʔɛm] (listen); both from German inoffizieller Mitarbeiter), or euphemistically informal collaborator (informeller Mitarbeiter), was an informant in the German Democratic Republic (East Germany)  who delivered private information to the Ministry for State Security (MfS / Stasi). At the end of the East German government, there was a network of around 189,000 informants, working at every level of society.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Collaborative_fiction">Collaborative fiction</a></td>
      <td>Collaborative fiction is a form of writing by a group of authors who share creative control of a story.\nCollaborative fiction can occur for commercial gain, as part of education, or recreationally – many collaboratively written works have been the subject of a large degree of academic research.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Collaborative_engineering">Collaborative engineering</a></td>
      <td>Collaborative engineering is defined by the International Journal of Collaborative Engineering as a discipline that "studies the interactive process of engineering collaboration, whereby multiple interested stakeholders resolve conflicts, bargain for individual or collective advantages, agree upon courses of action, and/or attempt to craft joint outcomes which serve their mutual interests."Collaborative engineering is quickly becoming a topic of great interest in recent years due to the explosion of internet technologies. This upsurge is partially due to the success of projects such as Wikipedia and Linux that have proven the efficacy of internet collaboration.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_frequent_David_Lynch_collaborators">List of frequent David Lynch collaborators</a></td>
      <td>David Keith Lynch (born January 20, 1946) is an American filmmaker, painter, television director, visual artist, musician, and occasional actor. Known for his surrealist films, he has developed his own unique cinematic style, known as "Lynchian"; this style is characterized by its dream imagery and meticulous sound design.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Australian_Government">Australian Government</a></td>
      <td>The Australian Government, also known as the Commonwealth Government, is the national government of Australia, a federal parliamentary constitutional monarchy. Like other Westminster-style systems of government, the Australian Government is made up of three branches: the executive (the prime minister, the ministers, and government departments), the legislative (the Parliament of Australia), and the judicial.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Local_government">Local government</a></td>
      <td>Local government is a generic term for the lowest tiers of public administration within a particular sovereign state. This particular usage of the word government refers specifically to a level of administration that is both geographically-localised and has limited powers.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Government_agency">Government agency</a></td>
      <td>A government or state agency, sometimes an appointed commission, is a permanent or semi-permanent organization in the machinery of government that is responsible for the oversight and administration of specific functions, such as an administration. There is a notable variety of agency types.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Government_of_Canada">Government of Canada</a></td>
      <td>The government of Canada (French: gouvernement du Canada) is the body responsible for the federal administration of Canada. A constitutional monarchy, the Crown is the corporation sole, assuming distinct roles: the executive, as the Crown-in-Council; the legislature, as the Crown-in-Parliament; and the courts, as the Crown-on-the-Bench.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>IMCLONE SYSTEMS INC      ITEM 1A RISK FACTORS       Risks Relating to Our Business and Other Matters       The outcome of the review of our <font color="blue"><font color="blue">strategic alternatives</font> currently</font> being     performed by the Company with the assistance of Lazard is uncertain</td>
    </tr>
    <tr>
      <td>We recently announced that our <font color="blue">Board of Directors </font>has engaged the investment     bank Lazard to conduct, in <font color="blue">conjunction</font> with <font color="blue">management</font>, a full review of the     Company’s  <font color="blue">strategic alternatives</font> to <font color="blue">maximize shareholder value</font></td>
    </tr>
    <tr>
      <td><font color="blue">These     </font><font color="blue">alternatives could</font> include a merger, sale or <font color="blue">strategic alliance</font></td>
    </tr>
    <tr>
      <td>We are     proceeding in consultation with our <font color="blue">existing partners as</font> the process moves     forward</td>
    </tr>
    <tr>
      <td>It is <font color="blue">uncertain whether</font> any <font color="blue">particular strategic alternative will</font>     be pursued or that any <font color="blue">transaction will</font> occur, or on what terms</td>
    </tr>
    <tr>
      <td>We do not     plan to <font color="blue">release <font color="blue">additional</font></font> information about the status of the review of     <font color="blue">alternatives until</font> a <font color="blue">definitive <font color="blue">agreement</font></font> is <font color="blue">entered into</font> or the process is     otherwise completed</td>
    </tr>
    <tr>
      <td><font color="blue">Royalty  </font>and  <font color="blue">manufacturing</font>  revenue from sales of ERBITUX represent a     substantial portion of our revenues</td>
    </tr>
    <tr>
      <td><font color="blue">If ERBITUX </font>does not receive continued     market acceptance, sales may not continue and we may not <font color="blue">earn sufficient</font>     revenues</td>
    </tr>
    <tr>
      <td>Our <font color="blue">future growth</font> and a <font color="blue">significant</font> portion of our <font color="blue">future revenues <font color="blue">depend on</font></font>     the <font color="blue">continued commercial success</font> of ERBITUX, our only FDA-approved product</td>
    </tr>
    <tr>
      <td>We cannot be certain that ERBITUX <font color="blue">will continue</font> to be licensed or approved     in the <font color="blue">United States </font>or in any <font color="blue">foreign market</font></td>
    </tr>
    <tr>
      <td>A number of <font color="blue">factors may</font>     affect the rate and level of market acceptance of ERBITUX, including:       ·       The <font color="blue">perception by physicians</font> and other members of the healthcare     <font color="blue">community</font> of ERBITUX’s safety or efficacy or that of competing products;       ·       The <font color="blue"><font color="blue">effective</font>ness</font> of our and BMS’ sales and marketing efforts in the     <font color="blue">United States </font>and the <font color="blue"><font color="blue">effective</font>ness</font> of Merck KGaA’s sales and marketing     <font color="blue">efforts outside</font> the United States;       ·       The ability to obtain <font color="blue">additional</font> FDA approvals to market ERBITUX in     <font color="blue">additional</font> treatment <font color="blue"><font color="blue">indication</font>s</font> and tumor types;       ·       Any <font color="blue">unfavorable publicity concerning</font> ERBITUX or <font color="blue">competitive</font> drugs;       ·        The  price  of  ERBITUX  relative to other drugs or competing     <font color="blue">treatments</font>;       ·       The <font color="blue">availability</font> and level of third-party <font color="blue">reimbursement</font> for sales of     ERBITUX;       ·       The continued <font color="blue">availability</font> of <font color="blue">adequate supplies</font> of ERBITUX to meet     demand; and       ·       <font color="blue">Regulatory </font><font color="blue"><font color="blue">development</font>s</font> related to the <font color="blue">manufacture</font> or <font color="blue">continued use</font>     of <font color="blue">ERBITUX     </font>  <font color="blue">If ERBITUX </font>does not continue to be accepted, our <font color="blue">revenues would decline</font>,     <font color="blue">which would impact</font> our <font color="blue">profitability</font> and the price of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">depend on</font> <font color="blue"><font color="blue">BMS and Merck </font>KGaA </font>to co-promote market and sell <font color="blue">ERBITUX If     </font>either <font color="blue">BMS or Merck KGaA </font><font color="blue">becomes unable</font> to meet its <font color="blue">obligations</font>, or we fail     to  <font color="blue">adequately</font> maintain our <font color="blue">relationship with</font> these partners, it would     <font color="blue"><font color="blue">negatively</font> impact</font> our revenues and harm our business</td>
    </tr>
    <tr>
      <td>Under our <font color="blue"><font color="blue">agreement</font> with</font> BMS, BMS has the exclusive right to distribute     ERBITUX in the <font color="blue">United States </font>and Canada, in exchange for which we receive     royalty payments of 39prca of BMS’ net sales of ERBITUX in the <font color="blue">United States </font>    and Canada</td>
    </tr>
    <tr>
      <td>Under our <font color="blue"><font color="blue">agreement</font> with</font> Merck KGaA, Merck has the exclusive     right to market ERBITUX outside of the United States, Canada and Japan, in     exchange for which we receive royalty payments based on Merck’s gross profit     from ERBITUX sales</td>
    </tr>
    <tr>
      <td>These <font color="blue">royalty payments from</font> <font color="blue">BMS and Merck </font>represent a     <font color="blue">significant</font>  portion  of our <font color="blue">current revenues</font></td>
    </tr>
    <tr>
      <td>In addition, we receive     <font color="blue">milestone payments</font> and <font color="blue"><font color="blue">reimbursement</font>s</font> of <font color="blue">various <font color="blue">regulatory</font></font> and clinical     <font color="blue">expenses as well as</font>       40     ______________________________________________________________________       certain  marketing and <font color="blue">administrative expenses from</font> BMS and Merck</td>
    </tr>
    <tr>
      <td>Our     reliance  on  these <font color="blue">relationships</font> creates a number of <font color="blue">potential risks</font>,     including the risk that we may be unable to <font color="blue">control whether</font> our corporate     <font color="blue">partners devote sufficient resources</font> to our programs or product</td>
    </tr>
    <tr>
      <td>If either     BMS  or Merck <font color="blue">becomes unable</font> to <font color="blue">market <font color="blue">effective</font>ly</font> and <font color="blue">sell sufficient</font>     quantities  of  ERBITUX,  or  otherwise unable to meet its <font color="blue">contractual</font>     <font color="blue">obligations</font>, our revenues would be <font color="blue"><font color="blue">negatively</font> impact</font>ed and it would harm our     business</td>
    </tr>
    <tr>
      <td>We operate in a highly <font color="blue">competitive</font> industry, including in terms of product     pricing, that is subject to rapid and <font color="blue">significant</font> technological change</td>
    </tr>
    <tr>
      <td>The <font color="blue"><font color="blue">pharmaceutical</font> industry</font> in which we operate is highly <font color="blue">competitive</font></td>
    </tr>
    <tr>
      <td>Our     present  and  potential  <font color="blue">competitors</font>  include <font color="blue">major <font color="blue">pharmaceutical</font></font> and     <font color="blue">bio<font color="blue">technology</font></font> companies, as well as specialty <font color="blue">pharmaceutical</font> firms</td>
    </tr>
    <tr>
      <td><font color="blue">Certain     </font>of these companies have <font color="blue">considerably</font> greater financial, research, clinical,     <font color="blue">regulatory</font>, <font color="blue">manufacturing</font>, and marketing resources than we do</td>
    </tr>
    <tr>
      <td>We have     already  experienced  <font color="blue">significant</font> <font color="blue">competition</font> to ERBITUX from Avastin®     (<font color="blue">bevacizumab</font>) (a non-<font color="blue">chemotherapeutic</font> <font color="blue">bio<font color="blue">pharmaceutical</font></font> product <font color="blue">manufacture</font>d     by Genentech, Inc</td>
    </tr>
    <tr>
      <td>and <font color="blue">approved by</font> the FDA as a first-line treatment for     <font color="blue"><font color="blue">patients with metastatic</font> <font color="blue">colorectal cancer</font></font>) and Xeloda® (a <font color="blue">chemotherapeutic</font>     <font color="blue">bio<font color="blue">pharmaceutical</font></font> product <font color="blue">manufacture</font>d by Roche Laboratories, Inc</td>
    </tr>
    <tr>
      <td>and also     <font color="blue">approved by</font> the FDA as a first-line treatment for <font color="blue">patients with metastatic</font>     <font color="blue">colorectal cancer</font>)</td>
    </tr>
    <tr>
      <td>We believe that, <font color="blue">notwithstanding</font> the fact that the FDA     has approved Avastin®, Xeloda® and ERBITUX for the treatment of metastatic     <font color="blue">colorectal cancer</font> in different <font color="blue"><font color="blue">indication</font>s</font>, physicians have prescribed     Avastin®  and Xeloda® outside of their approved <font color="blue"><font color="blue">indication</font>s</font> and within     ERBITUX’s approved <font color="blue"><font color="blue">indication</font>s</font></td>
    </tr>
    <tr>
      <td>We are also aware of products in <font color="blue">development</font>     at other <font color="blue">bio<font color="blue">technology</font></font> or <font color="blue"><font color="blue">pharmaceutical</font> companies</font> that, if successful in     <font color="blue">clinical trials</font> and approved for marketing, may be priced <font color="blue">competitive</font>ly and     <font color="blue">compete with</font> ERBITUX for the <font color="blue">indication</font> for which we have FDA approval, or     for  <font color="blue"><font color="blue">indication</font>s</font>  for which we are seeking, or may seek, FDA approval</td>
    </tr>
    <tr>
      <td>Business <font color="blue">combinations among</font> our <font color="blue">competitors</font> may increase <font color="blue">competition</font> and the     <font color="blue">resources available</font> to these <font color="blue">competitors</font></td>
    </tr>
    <tr>
      <td>In addition, the <font color="blue">pharmaceutical</font>     industry has undergone, and is expected to continue to undergo, rapid and     <font color="blue">significant</font> technological change, and we expect <font color="blue">competition</font> to <font color="blue">increase with</font>     technical  advances</td>
    </tr>
    <tr>
      <td>The  <font color="blue">development</font> of products or <font color="blue">processes by</font> our     <font color="blue">competitors</font> with <font color="blue">significant</font> advantages over those that we are seeking to     develop  could  cause the <font color="blue">marketability</font> of our products to stagnate or     decline</td>
    </tr>
    <tr>
      <td>We are subject to extensive <font color="blue"><font color="blue">government</font>al regulation</font></td>
    </tr>
    <tr>
      <td>If we are unable to     obtain  or  maintain  <font color="blue">regulatory</font>  approvals for our product or product     <font color="blue">candidates</font>, we will not be able to market our product or further develop our     product <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>We are subject to <font color="blue">stringent regulation <font color="blue">with respect</font></font> to <font color="blue">product safety</font> and     efficacy  by  various  <font color="blue">international</font> and US federal, state and local     <font color="blue">authorities</font></td>
    </tr>
    <tr>
      <td>Of <font color="blue">particular significance</font> are the FDA’s <font color="blue"><font color="blue">requirement</font>s covering</font>     research and <font color="blue">development</font>, testing, <font color="blue">manufacturing</font>, quality control, labeling     and promotion of drugs for human use</td>
    </tr>
    <tr>
      <td>Any <font color="blue">bio<font color="blue">pharmaceutical</font></font> that we may     develop cannot be marketed in the <font color="blue">United States </font>until it has <font color="blue">been approved</font>     by the FDA, and then can only be marketed for the <font color="blue"><font color="blue">indication</font>s</font> and claims     <font color="blue">approved by</font> the FDA As a result of these <font color="blue">requirement</font>s, the length of time,     the  level of <font color="blue">expenditures</font> and the <font color="blue">laboratory</font> and clinical information     required for approval of an NDA or a BLA, or any <font color="blue">supplements thereto</font>, are     substantial and can require a number of years, and the ability to obtain     <font color="blue">regulatory</font> approval is uncertain</td>
    </tr>
    <tr>
      <td>In addition, after any of our products     receives <font color="blue">regulatory</font> approval, it remains subject to ongoing FDA regulation,     including  with  respect  to, for example, changes to the product, its     <font color="blue">manufacturing</font>  or  label,  new  or revised <font color="blue">regulatory</font> <font color="blue">requirement</font>s for     <font color="blue">manufacturing</font> practices, <font color="blue">additional</font> clinical study <font color="blue">requirement</font>s, restricted     <font color="blue">distribution</font>,  written  warnings  to physicians, a <font color="blue">product recall</font>, and     withdrawal of a <font color="blue">previously</font> obtained approval</td>
    </tr>
    <tr>
      <td><font color="blue">Similarly </font>extensive regulation     exists outside of the United States, including in <font color="blue">Europe and Japan</font></td>
    </tr>
    <tr>
      <td>41     ______________________________________________________________________       We cannot be sure that we will be able to receive necessary <font color="blue">regulatory</font>     <font color="blue">approvals on</font> a <font color="blue">timely basis</font>, if at all, for any of the product <font color="blue">candidates</font> we     are developing or that we can maintain or receive any <font color="blue">additional</font> necessary     <font color="blue">regulatory</font> approvals for <font color="blue">ERBITUX Any </font>delay in obtaining <font color="blue">such approval</font> or     failure to maintain <font color="blue">regulatory</font> approvals could prevent us from marketing our     product and would have a material adverse effect on our business</td>
    </tr>
    <tr>
      <td>Moreover, it is possible that the current <font color="blue">regulatory</font> framework could change     or  <font color="blue">additional</font> regulations could arise at any <font color="blue">stage during</font> our product     <font color="blue">development</font> or marketing processes, which may affect our ability to obtain     or maintain approval of our products</td>
    </tr>
    <tr>
      <td>Our <font color="blue">revenues will diminish</font> if our <font color="blue"><font color="blue">collaborators</font> fail</font> to obtain acceptable     prices or <font color="blue">adequate <font color="blue">reimbursement</font></font> for ERBITUX from third-party payors</td>
    </tr>
    <tr>
      <td>All our revenues from ERBITUX are <font color="blue">based on sales</font> of the <font color="blue">product by</font> our two     <font color="blue">collaborators</font>,  <font color="blue"><font color="blue">BMS and Merck </font>KGaA </font>The <font color="blue">continuing efforts</font> of US and     foreign <font color="blue">government</font> and third-party payors to contain or reduce the costs of     health care may limit the revenues that we earn from these sales of <font color="blue">ERBITUX     </font>If <font color="blue">government</font> and other third-party payors do not <font color="blue">provide adequate coverage</font>     and <font color="blue">reimbursement</font> for our product, physicians may not prescribe it</td>
    </tr>
    <tr>
      <td>In  some  foreign  markets,  pricing and <font color="blue">profitability</font> of <font color="blue">prescription</font>     <font color="blue">pharmaceutical</font>s are subject to <font color="blue">government</font> control</td>
    </tr>
    <tr>
      <td>In the United States,     there is, and we expect that there <font color="blue">will continue</font> to be, federal, state and     <font color="blue">local <font color="blue">legislation</font> aimed at imposing</font> similar controls</td>
    </tr>
    <tr>
      <td>In addition, we expect     <font color="blue">managed care initiatives</font> in the <font color="blue">United States </font>to continue to put pressure on     the pricing of <font color="blue">pharmaceutical</font> products</td>
    </tr>
    <tr>
      <td>Cost <font color="blue">control initiatives would</font>     decrease the price received by our <font color="blue">collaborators</font> for any of our products in     the future</td>
    </tr>
    <tr>
      <td>Further, cost <font color="blue">control initiatives would</font> impair or diminish our     ability  or  incentive, or the ability or incentive of our partners or     <font color="blue">potential partners</font>, to <font color="blue">commercialize</font> our other product <font color="blue">candidates</font>, and     <font color="blue">accordingly</font>, our ability to <font color="blue">earn revenues</font></td>
    </tr>
    <tr>
      <td>Our ability to <font color="blue">commercialize</font> any other product <font color="blue">candidates</font>, alone or with     <font color="blue">collaborators</font>,  <font color="blue">will continue</font> to depend in part on the <font color="blue">availability</font> of     <font color="blue">reimbursement</font> from:       ·       <font color="blue">government</font> and health <font color="blue">administration</font> <font color="blue">authorities</font>, including <font color="blue">Medicare     </font>and Medicaid;       ·       <font color="blue">private health insurers</font>; and       ·       other third-party payors</td>
    </tr>
    <tr>
      <td>Third-party payors, including Medicare, are <font color="blue">increasingly challenging</font> the     <font color="blue">prices charged</font> for <font color="blue">medical products</font> and services</td>
    </tr>
    <tr>
      <td><font color="blue">Government </font>and other     third-party payors increasingly are <font color="blue">limiting both coverage</font> and level of     <font color="blue">reimbursement</font> for new drugs and, in some cases, refusing to <font color="blue">provide coverage</font>     for a patient’s use of an <font color="blue">approved drug</font> for purposes not <font color="blue">approved by</font> the     FDA       Our royalty and <font color="blue">collaborative</font> <font color="blue">agreement</font> revenues could vary <font color="blue">significant</font>ly     and <font color="blue">may <font color="blue">adversely</font> impact</font> our business</td>
    </tr>
    <tr>
      <td>Royalty and <font color="blue">collaborative</font> <font color="blue">agreement</font> revenues in future periods could vary     <font color="blue">significant</font>ly</td>
    </tr>
    <tr>
      <td>Major <font color="blue">factors affecting</font> these revenues include, but are not     limited to:       ·       Variations in BMS’ and Merck KGaA’s and other licensees’ sales of     licensed products;       ·       The expiration or <font color="blue">termination</font> of existing arrangements with our     <font color="blue">collaborative</font> partners, particularly Merck KGaA and BMS, which may include     <font color="blue">development</font> and <font color="blue">marketing arrangements</font> for our products in the US, Europe     and other <font color="blue">countries outside</font> the United States;       ·       The timing of US and non-US approvals, if any, for our products     licensed to BMS, Merck KGaA and other licensees;       42     ______________________________________________________________________       ·       The <font color="blue">initiation</font> of new <font color="blue">collaborative</font> <font color="blue">agreement</font>s with other companies;       ·       Whether and when <font color="blue">collaborative</font> <font color="blue">agreement</font> <font color="blue">benchmarks</font> and <font color="blue">milestones</font>     are achieved;       ·       The failure or refusal of a licensee to <font color="blue">pay royalties</font>;       ·        The  expiration  or  <font color="blue">invalidation</font>  of our patents or licensed     <font color="blue">intellectual property</font>;       ·       <font color="blue">Decreases </font>in licensees’ sales of our <font color="blue">products due</font> to <font color="blue">competition</font>,     <font color="blue">manufacturing</font> <font color="blue"><font color="blue">difficult</font>ies</font> or other <font color="blue">factors affecting</font> sales of products,     including any <font color="blue">safety issues</font>; and       ·       Disputes arising <font color="blue">with respect</font> to the <font color="blue">interpretation</font> of provisions in     existing or future <font color="blue">agreement</font>s with our <font color="blue">collaborative</font> partners</td>
    </tr>
    <tr>
      <td>If we are unable to <font color="blue">earn sufficient</font> revenues from ERBITUX, our operating     results or <font color="blue">financial condition could</font> be <font color="blue"><font color="blue">adversely</font> affected</font></td>
    </tr>
    <tr>
      <td>We  will  be required to expend <font color="blue">significant</font> resources for research and     <font color="blue">development</font> of our products in <font color="blue">development</font> and these <font color="blue">products may</font> not be     developed <font color="blue">successfully</font>, which would <font color="blue">adversely</font> affect our prospects for     <font color="blue">future revenue growth</font> and our stock price</td>
    </tr>
    <tr>
      <td>Our <font color="blue">only approved product</font> is ERBITUX while our product <font color="blue">candidates</font> are still     undergoing <font color="blue">clinical trials</font> and are in the <font color="blue">early stages</font> of <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>Any     successful <font color="blue">development</font> of our product <font color="blue">candidates</font> is <font color="blue">highly uncertain</font> and     <font color="blue">depends on</font> a number of factors, many of which are beyond our control</td>
    </tr>
    <tr>
      <td>In     addition, each of our product <font color="blue">candidates</font> under <font color="blue">development</font> will require     <font color="blue">significant</font> <font color="blue">additional</font> research and <font color="blue">development</font> resources to be expended     prior to their <font color="blue">commercialization</font></td>
    </tr>
    <tr>
      <td>Even if we spend substantial <font color="blue">amounts on</font>     research  and <font color="blue">development</font>, our potential <font color="blue">products may</font> not be developed     <font color="blue">successfully</font></td>
    </tr>
    <tr>
      <td>If  the  product  <font color="blue">candidates</font>  on which we have expended     <font color="blue">significant</font> amounts for research and <font color="blue">development</font> are not <font color="blue">commercialize</font>d, we     will not earn a return on their research and <font color="blue">development</font> <font color="blue">expenditures</font>, which     would <font color="blue">adversely</font> affect our prospects for <font color="blue">future revenue growth</font> and our stock     price</td>
    </tr>
    <tr>
      <td><font color="blue">Difficulties </font>or delays in product <font color="blue">manufacturing</font> and finishing could cause     shortfalls in the supply of ERBITUX or our product <font color="blue">candidates</font> currently     being developed which would harm our business and, in the case of ERBITUX,     our ability to meet our financial <font color="blue">obligations</font></td>
    </tr>
    <tr>
      <td><font color="blue">Cardinal Health Inc</font></td>
    </tr>
    <tr>
      <td>is currently our <font color="blue">sole provider</font> of filling and finishing     services—the final stage of <font color="blue">manufacturing</font> for <font color="blue">ERBITUX In </font>addition, we     currently <font color="blue">manufacture</font> ERBITUX at our BB36 <font color="blue">manufacturing</font> facility and through     <font color="blue">Cardinal Health Inc</font></td>
    </tr>
    <tr>
      <td>Any <font color="blue">prolonged interruption</font> in the <font color="blue">operations</font> of our or     our <font color="blue">contractors</font>’ <font color="blue">manufacturing</font> and finishing <font color="blue"><font color="blue">facilities</font> could</font> result in     <font color="blue">cancellations</font>  of  shipments,  loss of product in the process of being     <font color="blue">manufacture</font>d, or a shortfall of <font color="blue">available product inventory</font></td>
    </tr>
    <tr>
      <td>A number of     factors  could  cause interruptions, including a failure of our or our     <font color="blue">contractors</font>’ <font color="blue">manufacturing</font> and finishing <font color="blue">facilities</font> to obtain FDA approval     and  maintain  compliance  with  current  good  <font color="blue">manufacturing</font> practice     <font color="blue">requirement</font>s, changes in the FDA’s <font color="blue">regulatory</font> <font color="blue">requirement</font>s or standards that     require <font color="blue">modifications</font> to our <font color="blue">manufacturing</font> processes, action by the FDA that     results in the halting of production of one or more of our <font color="blue">products due</font> to     <font color="blue">regulatory</font> issues, a contract <font color="blue">manufacture</font>r going out of business, natural or     other <font color="blue">disasters</font>, or other similar factors</td>
    </tr>
    <tr>
      <td>Because our <font color="blue">manufacturing</font> and     finishing processes and those of our <font color="blue">contractors</font> are <font color="blue">highly complex</font> and are     subject to a lengthy FDA <font color="blue">approval process</font> and extensive <font color="blue">ongoing regulation</font>,     <font color="blue">alternative qualified production capacity may</font> not be <font color="blue">available on</font> a timely     basis or at all</td>
    </tr>
    <tr>
      <td>We may also experience insufficient available capacity to     <font color="blue">manufacture</font>  existing  or <font color="blue">new products which could</font> cause shortfalls of     available  product  inventory</td>
    </tr>
    <tr>
      <td><font color="blue">Difficulties </font> or delays in our and our     <font color="blue">contractors</font>’ <font color="blue">manufacturing</font> and supply of existing or new products could     increase our costs, cause us to lose revenue or market share and damage our     reputation</td>
    </tr>
    <tr>
      <td>43     ______________________________________________________________________       <font color="blue">Although the FDA </font>has approved our BB36 <font color="blue">manufacturing</font> <font color="blue">facilities</font> and the     <font color="blue">facilities</font> have <font color="blue">passed multiple subsequent inspections</font>, if we are unable to     maintain FDA approval for BB36, it may cause shortfalls in our product     inventory which would <font color="blue"><font color="blue">negatively</font> impact</font> our revenues and our business</td>
    </tr>
    <tr>
      <td>Our <font color="blue">marketing partners may</font> experience pressure to lower the price of <font color="blue">ERBITUX     </font>because of new and/or proposed federal <font color="blue">legislation</font>, <font color="blue">which would reduce</font> our     <font color="blue">royalty revenue</font> and may harm our business</td>
    </tr>
    <tr>
      <td><font color="blue">Federal  </font><font color="blue"><font color="blue">legislation</font> enacted</font> in <font color="blue">December </font>2003 altered the way in which     <font color="blue">physician administered drugs covered by</font> Medicare, such as ERBITUX, are     reimbursed,  <font color="blue">generally</font>  leading  to  lower  <font color="blue">reimbursement</font> levels</td>
    </tr>
    <tr>
      <td><font color="blue">This     </font><font color="blue"><font color="blue">legislation</font> also added</font> an outpatient <font color="blue">prescription</font> drug benefit to Medicare,     <font color="blue">effective</font> January 2006</td>
    </tr>
    <tr>
      <td>The outpatient <font color="blue">prescription</font> drug benefit is provided     primarily through private entities, which will attempt to <font color="blue">negotiate price</font>     concessions from <font color="blue">pharmaceutical</font> <font color="blue">manufacture</font>rs, including our <font color="blue">collaborators</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">negotiations may increase pressures</font> to <font color="blue">lower pricing</font> for <font color="blue">ERBITUX     </font>While the law <font color="blue">specifically</font> prohibits the <font color="blue">United States </font><font color="blue">government</font> from     <font color="blue">interfering</font> in price negotiations between <font color="blue">manufacture</font>rs and Medicare drug     plan sponsors, some members of <font color="blue">Congress </font>are <font color="blue">pursuing <font color="blue">legislation</font></font> that would     permit the <font color="blue">United States </font><font color="blue">government</font> to use its enormous <font color="blue">purchasing power</font> to     demand discounts from <font color="blue"><font color="blue">pharmaceutical</font> companies</font>, thereby creating de facto     price controls on <font color="blue">prescription</font> drugs, such as <font color="blue">ERBITUX In </font>addition, the new     <font color="blue">law contains triggers</font> for <font color="blue">Congressional </font><font color="blue">consideration</font> of <font color="blue">cost <font color="blue">containment</font></font>     measures for Medicare in the event Medicare <font color="blue">cost increases exceed</font> a certain     level</td>
    </tr>
    <tr>
      <td>These  cost  <font color="blue">containment</font>  <font color="blue">measures could</font> include some sorts of     limitations on <font color="blue">prescription</font> drug prices that our <font color="blue">collaborators</font> charge for     ERBITUX <font color="blue">which would reduce</font> our <font color="blue">royalty revenue</font> and harm our business</td>
    </tr>
    <tr>
      <td>If  we become subject to <font color="blue">importation</font> of <font color="blue">products from</font> Canada and other     countries, it will affect our <font color="blue">profitability</font> and harm our business</td>
    </tr>
    <tr>
      <td>ERBITUX  and  other products that we may develop may become subject to     <font color="blue">competition</font>  from  lower  priced imports from Canada, Mexico and other     countries where <font color="blue">government</font> price controls or other <font color="blue">market dynamics</font> have     resulted  in  <font color="blue">lower priced products</font></td>
    </tr>
    <tr>
      <td>The ability of patients and other     customers to obtain these <font color="blue">lower priced imports</font> has grown <font color="blue">significant</font>ly as a     result of the Internet, an expansion of pharmacies in Canada and elsewhere     targeted <font color="blue">to American </font>purchasers, the increase in US-based <font color="blue">businesses</font>     <font color="blue">affiliated with</font> <font color="blue">Canadian </font><font color="blue">pharmacies marketing</font> <font color="blue">to American </font>purchasers and     other factors</td>
    </tr>
    <tr>
      <td>However,  the  volume  of imports continues to rise due to the limited     <font color="blue"><font color="blue">enforcement</font> resources</font> of the FDA and the US Customs Service, and the     pressure in the <font color="blue">current political environment</font> to permit the <font color="blue">imports as</font> a     mechanism for <font color="blue">expanding access</font> to <font color="blue">lower priced medicines</font></td>
    </tr>
    <tr>
      <td>In addition, in <font color="blue">December </font>2003, federal <font color="blue">legislation</font> was enacted to modify     United  States  import  laws  and  expand the ability for lower priced     <font color="blue">pharmaceutical</font> products to be <font color="blue">imported from</font> Canada, where <font color="blue">government</font> price     controls have <font color="blue">been enacted</font></td>
    </tr>
    <tr>
      <td>These changes to the <font color="blue"><font color="blue">import laws</font> will</font> not take     effect unless and until the <font color="blue"><font color="blue"><font color="blue">Secretary </font>of Health </font>and Human Services </font>certifies     that the changes will lead to substantial savings for consumers and will not     create a <font color="blue">public health safety issue</font></td>
    </tr>
    <tr>
      <td>The current <font color="blue"><font color="blue">Secretary </font>of Health </font>and     Human  Services has indicated that there is not a basis to make such a     <font color="blue"><font color="blue">certification</font> at</font> this time</td>
    </tr>
    <tr>
      <td>However, it is possible that this <font color="blue">Secretary </font>or a     subsequent <font color="blue">Secretary </font>could make such a <font color="blue">certification</font> in the future</td>
    </tr>
    <tr>
      <td>In addition, <font color="blue">legislation</font> has <font color="blue">been proposed</font> to implement the changes to the     <font color="blue"><font color="blue">import laws</font> without</font> any <font color="blue">requirement</font> for <font color="blue">certification</font> from the <font color="blue">Secretary </font>of     Health and Human Services, and to <font color="blue">broaden permissible imports</font> in other ways</td>
    </tr>
    <tr>
      <td>Even if these changes to the <font color="blue">import laws</font> do not take effect, and other     changes are not enacted, <font color="blue">lower priced imports</font> of <font color="blue">products from</font> Canada and     elsewhere may continue to increase due to market and political forces, and     the limited <font color="blue"><font color="blue">enforcement</font> resources</font> of the FDA, the US Customs Service, and     other <font color="blue">government</font> agencies</td>
    </tr>
    <tr>
      <td>For example, state and local <font color="blue">government</font>s have     suggested that they <font color="blue">may import drugs from</font> Canada for employees covered by     state health plans or others, and some have already enacted such plans</td>
    </tr>
    <tr>
      <td>44     ______________________________________________________________________       Lower priced imports will <font color="blue">adversely</font> affect our <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>This impact     <font color="blue">could become</font> more <font color="blue">significant</font> in the future, and the <font color="blue">impact could</font> be even     greater  if  there is a further change in the law or if state or local     <font color="blue">government</font>s take further steps to permit <font color="blue">lower priced imports</font> from abroad</td>
    </tr>
    <tr>
      <td>We <font color="blue">depend on</font> <font color="blue">key employee</font>s in a <font color="blue">competitive</font> market for <font color="blue">skilled personnel</font>,     and the loss of the services of any of our <font color="blue"><font color="blue">key employee</font>s would affect</font> our     ability to develop our business</td>
    </tr>
    <tr>
      <td>We  are  highly  <font color="blue">dependent on</font> the <font color="blue">principal members</font> of our <font color="blue">management</font>,     <font color="blue">operations</font> and <font color="blue">scientific staff</font></td>
    </tr>
    <tr>
      <td>We experience intense <font color="blue">competition</font> for     <font color="blue">qualified personnel</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">future <font color="blue">success depends</font></font> in part on the continued     service of our executive <font color="blue">management</font> and <font color="blue">scientific personnel</font> and our ability     to  recruit, train and retain highly qualified <font color="blue">management</font>, scientific,     <font color="blue">manufacturing</font> and sales and <font color="blue">marketing personnel</font></td>
    </tr>
    <tr>
      <td>If we lose the services of     any of these personnel, our research and product <font color="blue">development</font> and marketing     goals, including the maintenance of <font color="blue">relationships</font> with leading research     <font color="blue">institutions</font>  and key <font color="blue">collaborators</font>, could be delayed or curtailed</td>
    </tr>
    <tr>
      <td>In     addition,  we  do  not maintain “key man” life insurance on any of our     employees</td>
    </tr>
    <tr>
      <td>As a result, we may be unable to minimize the negative impact on     our business stemming from the loss of a <font color="blue">key employee</font></td>
    </tr>
    <tr>
      <td>The  law  or FDA <font color="blue">policy could</font> change and expose us to <font color="blue">competition</font> from     “generic” or “follow-on” versions of our products, which may impact our     market share and harm our business</td>
    </tr>
    <tr>
      <td>Under current US law and FDA policy, generic versions of <font color="blue">conventional</font>     chemical drug compounds, sometimes referred to as small molecule compounds,     may be <font color="blue">approved through</font> an abbreviated <font color="blue">approval process</font></td>
    </tr>
    <tr>
      <td>In <font color="blue">general terms</font>,     the <font color="blue"><font color="blue">generic applicant</font> references</font> an approved innovator product for which     full <font color="blue">clinical data demonstrating safety</font> and <font color="blue"><font color="blue">effective</font>ness</font> exist for the     approved  <font color="blue">conditions</font>  of  use</td>
    </tr>
    <tr>
      <td>The <font color="blue">generic applicant</font> in turn need only     <font color="blue">demonstrate</font> that its product has the same active ingredient(s), dosage form,     strength, route of <font color="blue">administration</font>, and <font color="blue">conditions</font> of use (labeling) as the     <font color="blue">referenced innovator</font> drug, and that the <font color="blue">generic product</font> is absorbed in the     body at the same rate and to the <font color="blue">same extent as</font> the <font color="blue">referenced innovator</font>     drug (this is <font color="blue">known as bioequivalence</font>)</td>
    </tr>
    <tr>
      <td>In addition, the <font color="blue">generic application</font>     must  contain  information  regarding  the <font color="blue">manufacturing</font> processes and     <font color="blue">facilities</font> that will be used to <font color="blue">ensure product quality</font>, and must contain     <font color="blue">certification</font>s to <font color="blue">patents listed with</font> the FDA for the <font color="blue">referenced innovator</font>     drug</td>
    </tr>
    <tr>
      <td>There  is  no  such abbreviated <font color="blue">approval process</font> under current law for     <font color="blue"><font color="blue">biological products</font> approved under</font> the <font color="blue">Public Health Service Act </font>through a     BLA, such as monoclonal antibodies, cytokines, growth factors, enzymes,     <font color="blue">interferons</font> and certain other proteins</td>
    </tr>
    <tr>
      <td>However, <font color="blue">various proposals</font> have been     made to establish an abbreviated <font color="blue">approval process</font> to <font color="blue">permit approval</font> of     generic or follow-on versions of these types of <font color="blue">biological products</font></td>
    </tr>
    <tr>
      <td>The     proposals include proposals for <font color="blue">legislation</font>, and proposals for the FDA to     extend its <font color="blue">existing authority</font> to this area</td>
    </tr>
    <tr>
      <td>For example, some have proposed     that  the FDA allow a generic or follow-on copy of <font color="blue">certain therapeutic</font>     biologics  to  be  approved  under  an  existing  mechanism known as a     505(b)(2) application</td>
    </tr>
    <tr>
      <td>A 505(b)(2) application is a form of an NDA, where     the applicant does not have a right to reference some of the data being     <font color="blue">relied upon</font> for approval</td>
    </tr>
    <tr>
      <td>Under current regulations, 505(b)(2) applications     can be used where the applicant is relying in part <font color="blue">on published literature</font>     or  on  findings  of safety or <font color="blue"><font color="blue">effective</font>ness</font> in another company’s NDA     505(b)(2) applications have not been used to date for <font color="blue">therapeutic biologic</font>     products</td>
    </tr>
    <tr>
      <td>In  addition,  the  use  of 505(b)(2) applications even for     <font color="blue">conventional</font>  chemical  drug  products is the subject of <font color="blue">ongoing legal</font>     challenge</td>
    </tr>
    <tr>
      <td>It  is  thus  not  clear  what  the  permitted  use  of  a     505(b)(2) application might be in the future for <font color="blue">biologics products</font>, or     whether  any other <font color="blue">proposals on generic</font> or follow-on biologics will be     adopted</td>
    </tr>
    <tr>
      <td>However, if the law is changed or if the FDA <font color="blue">somehow extends</font> its     <font color="blue">existing authority</font> in new ways, and <font color="blue">third parties</font> are permitted to obtain     approvals  of versions of our <font color="blue">products through</font> an <font color="blue">abbreviated approval</font>     mechanism and <font color="blue">without conducting</font> full <font color="blue">clinical studies</font> of their own, it     could <font color="blue">adversely</font> affect our business</td>
    </tr>
    <tr>
      <td>Such <font color="blue">products would</font> be <font color="blue">significant</font>ly     <font color="blue">less costly than ours</font> to bring to market, and could lead to the existence of     multiple lower priced <font color="blue">competitive</font> products</td>
    </tr>
    <tr>
      <td>This <font color="blue">would <font color="blue">substantially</font> limit</font>     our ability to obtain a return on the <font color="blue">investments</font> we have made in those     products</td>
    </tr>
    <tr>
      <td>45     ______________________________________________________________________       Risks Relating to Intellectual Property and Legal Matters       Protecting our <font color="blue">proprietary rights</font> is <font color="blue">difficult</font> and costly</td>
    </tr>
    <tr>
      <td>If we fail to     <font color="blue">adequately</font> protect or enforce our <font color="blue">proprietary rights</font>, we <font color="blue">could lose revenue</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">success depends</font> in large part on our ability to obtain, maintain and     enforce our patents</td>
    </tr>
    <tr>
      <td>Our ability to <font color="blue">commercialize</font> any product <font color="blue">successfully</font>     will  largely  <font color="blue">depend on</font> our ability to obtain and maintain patents of     sufficient  scope  to prevent <font color="blue">third parties</font> from developing similar or     <font color="blue">competitive</font> products</td>
    </tr>
    <tr>
      <td>In the absence of patent protection, <font color="blue">competitors</font> may     cause  a  negative  impact to our business by developing and marketing     <font color="blue">substantially</font> equivalent products and <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>Patent disputes are frequent and can preclude the <font color="blue">commercialization</font> of     products</td>
    </tr>
    <tr>
      <td>We have in the past been, are currently, and may in the future be,     involved in material patent litigation, such as the <font color="blue">matters discussed under</font></td>
    </tr>
  </tbody>
</table>